Revolutionary CAR-T Therapy Offers Long-Term Hope for Lupus Patients

A groundbreaking treatment for lupus has shown long-term success since its first use in 2021. Researchers at the University of Erlangen in Bavaria achieved a major medical milestone by applying CAR-T cell therapy to a patient with systemic lupus erythematosus (SLE). This approach has since expanded globally, offering hope to those suffering from the chronic autoimmune disease.

Systemic lupus erythematosus (SLE) is a severe condition where the immune system mistakenly attacks healthy tissues. It can damage the skin, joints, kidneys, brain, heart, and lungs. Another form, cutaneous lupus erythematosus, affects only the skin. Common symptoms include joint pain, fatigue, fever, and a butterfly-shaped rash on the face.

The first successful CAR-T cell therapy for lupus took place at Erlangen University Hospital in March 2021. Led by Professor Georg Schett's team, the treatment targeted CD19 cells to reset the immune system. One patient, Thu-Thao V., a 20-year-old woman, received the therapy and has remained symptom-free for three years.

Since then, research has progressed rapidly. Multiple phase 1/2 trials have reported sustained remissions, with some patients showing no signs of disease for over three years. Leading medical centres, including Charité Berlin (2022), NYU Langone in New York (2023), the University of Pennsylvania (2024), and Amsterdam UMC (2024), have adopted similar methods. By early 2026, over 100 patients worldwide had undergone the treatment, with regulatory approvals for clinical trials accelerating in the US and Europe.

CAR-T cell therapy has transformed lupus treatment, moving from a single case in Erlangen to a globally recognised approach. With ongoing trials and expanding research, more patients may soon benefit from this innovative therapy. The method's success marks a significant step in managing a disease that once had limited treatment options.